Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
Immunostimulatory agents such as agonistic anti-CD137 and interleukin (IL)-2 generate effective anti-tumor immunity but also elicit serious toxicities, hampering their clinical application. Here we show that combination therapy with anti-CD137 and an IL-2-Fc fusion achieves significant initial anti-...
Main Authors: | Zhang, Yuan, Li, Na, Suh, Heikyung, Irvine, Darrell J |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biological Engineering |
Format: | Article |
Published: |
Nature Publishing Group
2018
|
Online Access: | http://hdl.handle.net/1721.1/115183 https://orcid.org/0000-0002-2931-7592 https://orcid.org/0000-0003-0787-298X |
Similar Items
-
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity
by: Yuan Zhang, et al.
Published: (2018-01-01) -
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
by: Marta Compte, et al.
Published: (2018-11-01) -
Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
by: Kwong, Brandon, et al.
Published: (2014) -
Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells
by: Zheng, Yiran, et al.
Published: (2020) -
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity
by: Oana Hangiu, et al.
Published: (2022-09-01)